Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia 2026
Added: 4 weeks ago Source:  Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the… View more

Guidelines & Statements

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 1 year ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions
Familial Hypercholesterolaemia in the Asia-Pacific Region
Author(s): Satoshi Honda , Jonathan Yap , Ivan Olegario , et al Added: 4 months ago

Prevention & Chronic Conditions
Transforming Outcomes with Lipid Clinics in Malaysia: Enablers and Barriers for the Implementation of Multidisciplinary Approach Clinics for the Management of Dyslipidaemia
Author(s): Azhari Rosman , Ahmad Khairuddin Mohamed Yusof , Hafidz Abd Hadi , et al Added: 1 month ago

Prevention & Chronic Conditions
Job title: Associate Adjunct Professor in Cardiology
Dr Payal Kohli is an Associate Adjunct Professor in Cardiology Division, Department of Medicine at Duke University and at Johns Hopkins University, US. Dr Kohli earned her undergraduate degree from Massachusetts Institute of Technology (MIT) with a perfect GPA and her medical degree from Harvard Medical School, magna cum laude. She is Board-certified in Internal Medicine, Cardiology and… View more
Post-ACS Discharge and Long-term Follow-up Recommendations for Thailand
Author(s): Rungroj Krittayaphong , Wacin Buddhari , Bancha Sookananchai , et al Added: 10 months ago

Intervention

MI/ACS
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions